ASX:TLXBiotechs
A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates
Telix Pharmaceuticals (ASX:TLX) has entered a busy regulatory phase, resubmitting its TLX101-Px New Drug Application for glioma imaging while also reporting that the lead-in stage of its TLX591-Tx Phase 3 prostate cancer trial met safety objectives.
See our latest analysis for Telix Pharmaceuticals.
These regulatory updates come after a strong short term run, with a 1 month share price return of 22.24% and a 7 day share price return of 12.93%. However, the 1 year total shareholder return is...